| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |